SANFILIPPO Aktie

 

This follows a similar endorsement by the US Food and Drug Administration (FDA). Sanfilippo syndrome type B is an autosomal recessive disease marked by mutations in the N-acetyl-alpha-glucosaminidase The post EC grants orphan drug status to JR-446 for MPS IIIB appeared first on Pharmaceutical Business review....

CATANIA, Italy--(BUSINESS WIRE)--A new era is beginning for Sicilian publishing. La Sicilia, the most widely read newspaper on the island and a reference point for millions of Sicilians worldwide, is now officially under the control of Palella Holdings, the family office led by Italian-American entrepreneur Salvatore Palella, originally from Acireale and long residing in the United States, from where he oversees numerous international business ventures. The transaction, finalized through the Sicily Investment Fund and the establishment of a new publishing company with Gianluca Spriano appointed as CEO, marks a historic handover after 80 uninterrupted years of management by the Ciancio Sanfilippo family. Through Dse, the family has published the newspaper since its founding in 1945 by Domenico Sanfilippo, a lawyer and landowner from Adrano. His grandson, Mario Ciancio Sanfilippo, led the paper for 51 years, becoming a central figure in Italian journalism, also serving as president of FIEG and vice presiden...

Acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application (BLA) Submission to U.S. FDA for TA-ERT Expected in 1H 2026 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. “With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by this devastating disease,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce. “Across the landscape, this is an incredibly important and exciting time for patients and families affected by neuropathic MPS diseases. Looking ahead, we remain focused on...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Diluted EPS Increased by 49.6% to $1.72 per Diluted Share ELGIN, Ill.--(BUSINESS WIRE)--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced financial results for its fiscal 2025 third quarter ended March 27, 2025. Third Quarter Summary Net sales decreased $11.0 million, or 4.0%, to $260.9 million Sales volume decreased 7.3 million pounds, or 7.9%, to 84.7 million pounds Gross profit increased 13.7% to $55.9 million Gross margin increased 3.3% to 21.4% Diluted EPS increased 49.6% to $1.72 per share CEO Commentary “Although we saw a decrease in sales volume during the third quarter, we improved our gross profit and achieved a 50% increase in diluted earnings per share. This was driven by, among other things, strategically controlling our costs and the continued alignment of our selling prices with increasing commodity acquisition costs. Like other snack food companies, our third quarter performance was impacted by a challenging macroeconomic and consumer environment. The sale...

Elgin, IL, April 23, 2025 (GLOBE NEWSWIRE) -- John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), a major processor and distributor of snack and recipe nut products and snack bar manufacturer, will hold its quarterly conference call to discuss its third quarter fiscal year 2025 operating results on Thursday, May 1, 2025 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). Third quarter fiscal 2025 results are expected to be released after the market closes on Wednesday, April 30, 2025....

Brings Deep Experience and Operational Expertise in the Hospitality and Gaming Industry' LAS VEGAS--(BUSINESS WIRE)--Wynn Resorts, Limited (NASDAQ: WYNN) announced today that Anthony Sanfilippo, former Chairman and Chief Executive Officer of Pinnacle Entertainment, has been nominated by the Wynn Resorts Board of Directors (the “Board”) as a director for election at the Company's 2025 Annual Meeting of Shareholders (“Annual Meeting”), to be held on April 30, 2025. Margaret “Dee Dee” Myers, who has served on the Board since 2018, has decided not seek re-election at the Annual Meeting. Mr. Sanfilippo is a seasoned executive in the hospitality and gaming industry who brings more than 35 years of experience and operational expertise to the Wynn Resorts Board. During his nearly decade-long tenure as the Chairman and CEO of Pinnacle Entertainment, Inc., Mr. Sanfilippo drove significant growth, leading multiple strategic transactions and organic growth initiatives. Prior to that, he served as Presid...

FDA decision expected by August 18, 2025 FDA decision expected by August 18, 2025...

Sanfilippo, James J. - Aufsichtsrat - Tag der Transaktion: 2025-02-11...

Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A....

Modified intent-to-treat group demonstrated +22.7 point (p...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Second Quarter Sales Volume Increased 7.1% with Volume Growth Across all Distribution Channels.ELGIN, Ill.--(BUSINESS WIRE)--John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced financial results for its fiscal 2025 second quarter ended December 26, 2024. Second Quarter Summary Net sales increased $9.8 million, or 3.4%, to $301.1 million Sales volume increased 6.4 million pounds, or 7.1%, to 96.3 million pounds Gross profit decreased 9.8% to $52.3 million Diluted EPS decreased 29.3% to $1.16 per share CEO Commentary “We are pleased to report our largest quarterly sales volume and highest quarterly net sales in our company's history in the second quarter. This achievement was driven by the second consecutive quarter of sales volume increases across all three of our distribution channels as we execute on our Long-Range Plan. Additionally, our bars sales volume increased by approximately 28% over the prior year quarter. We remain encouraged by the sales volume growth across ou...

Elgin, IL, Jan. 22, 2025 (GLOBE NEWSWIRE) -- John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), a major processor and distributor of snack and recipe nut products and snack bar manufacturer, will hold its quarterly conference call to discuss its second quarter fiscal year 2025 operating results on Thursday, January 30, 2025 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). Second quarter fiscal 2025 results are expected to be released after the market closes on Wednesday, January 29, 2025....

Sanfilippo, Jeffrey T. - Vorstand - Tag der Transaktion: 2025-01-16...

Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

Elgin, IL, Oct. 23, 2024 (GLOBE NEWSWIRE) -- John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), a major processor and distributor of snack and recipe nut products and snack bar manufacturer, will hold its quarterly conference call to discuss its first quarter fiscal year 2025 operating results on Thursday, October 31, 2024 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). First quarter fiscal 2025 results are expected to be released after the market closes on Wednesday, October 30, 2024....